Synopsis
Synopsis
0
JDMF
0
KDMF
0
VMF
0
Australia
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. 17603-42-8
2. 1,2,3-propanetriol, 1-(dihydrogen Phosphate), Sodium Salt
3. Sodium;2,3-dihydroxypropyl Hydrogen Phosphate
4. Sodium Alpha Glycerophosphate
5. Einecs 241-577-0
6. Alpha-natrium Glycerophosphat [german]
7. Alpha-natrium Glycerophosphat
8. 2,3-dihydroxypropyl (dihydrogen Phosphate), Sodium Salt
9. Disodium,1,3-dihydroxypropan-2-yl Phosphate,hydrate
10. Glycerol, 1-(dihydrogen Phosphate), Sodium Salt
11. Sodiumglycerophosphate
12. Sodium Alpha-glycerophosphate
13. 1,2,3-propentriol, 1-(dihydrogen Phosphate), Sodium Salt
14. Dtxsid70938740
15. Einecs 254-713-9
16. Akos006346295
17. Ft-0696352
18. A913951
19. 1,2,3-propanetriol, Mono(dihydrogen Phosphate), Sodium Salt
20. 1,2,3-propanetriol, 1-(dihydrogen Phosphate), Sodium Salt (1:?)
| Molecular Weight | 194.06 g/mol |
|---|---|
| Molecular Formula | C3H8NaO6P |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 4 |
| Exact Mass | 193.99561925 g/mol |
| Monoisotopic Mass | 193.99561925 g/mol |
| Topological Polar Surface Area | 110 Ų |
| Heavy Atom Count | 11 |
| Formal Charge | 0 |
| Complexity | 140 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 1 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CEP/COS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
DOSAGE - EMULSION;INTRAVENOUS - 2.4%;20MG/100...DOSAGE - EMULSION;INTRAVENOUS - 2.4%;20MG/100ML;6.8GM/100ML;68MG/100ML;124MG/100ML;170MG/100ML;105MG/100ML;3.5GM/100ML (1440ML)
USFDA APPLICATION NUMBER - 200656
DOSAGE - EMULSION;INTRAVENOUS - 2.4%;20MG/100...DOSAGE - EMULSION;INTRAVENOUS - 2.4%;20MG/100ML;6.8GM/100ML;68MG/100ML;124MG/100ML;170MG/100ML;105MG/100ML;3.5GM/100ML (1920ML)
USFDA APPLICATION NUMBER - 200656
DOSAGE - EMULSION;INTRAVENOUS - 2.4%;20MG/100...DOSAGE - EMULSION;INTRAVENOUS - 2.4%;20MG/100ML;6.8GM/100ML;68MG/100ML;124MG/100ML;170MG/100ML ;105MG/100ML;3.5GM/100ML (2400ML)
USFDA APPLICATION NUMBER - 200656
DOSAGE - EMULSION;INTRAVENOUS - 3.3%;29MG/100...DOSAGE - EMULSION;INTRAVENOUS - 3.3%;29MG/100ML;9.8GM/100ML;96MG/100ML;174MG/100ML;239MG/100ML ;147MG/100ML;3.9GM/100ML (1026ML)
USFDA APPLICATION NUMBER - 200656
DOSAGE - EMULSION;INTRAVENOUS - 3.3%;29MG/100...DOSAGE - EMULSION;INTRAVENOUS - 3.3%;29MG/100ML;9.8GM/100ML;96MG/100ML;174MG/100ML;239MG/100ML;147MG/100ML;3.9GM/100ML (1540ML)
USFDA APPLICATION NUMBER - 200656
DOSAGE - EMULSION;INTRAVENOUS - 3.3%;29MG/100...DOSAGE - EMULSION;INTRAVENOUS - 3.3%;29MG/100ML;9.8GM/100ML;96MG/100ML;174MG/100ML;239MG/100ML;147MG/100ML;3.9GM/100ML (2053ML)
USFDA APPLICATION NUMBER - 200656
DOSAGE - EMULSION;INTRAVENOUS - 3.3%;29MG/100...DOSAGE - EMULSION;INTRAVENOUS - 3.3%;29MG/100ML;9.8GM/100ML;96MG/100ML;174MG/100ML;239MG/100ML;147MG/100ML;3.9GM/100ML (2566ML)
USFDA APPLICATION NUMBER - 200656
Digital Content
DATA COMPILATION #PharmaFlow
Global Sales Information
Market Place
APIs
Reply
20 Aug 2024
Reply
15 May 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
ABOUT THIS PAGE
A Sodium Glycerophosphate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Sodium Glycerophosphate, including repackagers and relabelers. The FDA regulates Sodium Glycerophosphate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Sodium Glycerophosphate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Sodium Glycerophosphate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Sodium Glycerophosphate supplier is an individual or a company that provides Sodium Glycerophosphate active pharmaceutical ingredient (API) or Sodium Glycerophosphate finished formulations upon request. The Sodium Glycerophosphate suppliers may include Sodium Glycerophosphate API manufacturers, exporters, distributors and traders.
click here to find a list of Sodium Glycerophosphate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Sodium Glycerophosphate DMF (Drug Master File) is a document detailing the whole manufacturing process of Sodium Glycerophosphate active pharmaceutical ingredient (API) in detail. Different forms of Sodium Glycerophosphate DMFs exist exist since differing nations have different regulations, such as Sodium Glycerophosphate USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Sodium Glycerophosphate DMF submitted to regulatory agencies in the US is known as a USDMF. Sodium Glycerophosphate USDMF includes data on Sodium Glycerophosphate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Sodium Glycerophosphate USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Sodium Glycerophosphate suppliers with USDMF on PharmaCompass.
A Sodium Glycerophosphate CEP of the European Pharmacopoeia monograph is often referred to as a Sodium Glycerophosphate Certificate of Suitability (COS). The purpose of a Sodium Glycerophosphate CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Sodium Glycerophosphate EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Sodium Glycerophosphate to their clients by showing that a Sodium Glycerophosphate CEP has been issued for it. The manufacturer submits a Sodium Glycerophosphate CEP (COS) as part of the market authorization procedure, and it takes on the role of a Sodium Glycerophosphate CEP holder for the record. Additionally, the data presented in the Sodium Glycerophosphate CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Sodium Glycerophosphate DMF.
A Sodium Glycerophosphate CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Sodium Glycerophosphate CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Sodium Glycerophosphate suppliers with CEP (COS) on PharmaCompass.
A Sodium Glycerophosphate written confirmation (Sodium Glycerophosphate WC) is an official document issued by a regulatory agency to a Sodium Glycerophosphate manufacturer, verifying that the manufacturing facility of a Sodium Glycerophosphate active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Sodium Glycerophosphate APIs or Sodium Glycerophosphate finished pharmaceutical products to another nation, regulatory agencies frequently require a Sodium Glycerophosphate WC (written confirmation) as part of the regulatory process.
click here to find a list of Sodium Glycerophosphate suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Sodium Glycerophosphate as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Sodium Glycerophosphate API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Sodium Glycerophosphate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Sodium Glycerophosphate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Sodium Glycerophosphate NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Sodium Glycerophosphate suppliers with NDC on PharmaCompass.
Sodium Glycerophosphate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Sodium Glycerophosphate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Sodium Glycerophosphate GMP manufacturer or Sodium Glycerophosphate GMP API supplier for your needs.
A Sodium Glycerophosphate CoA (Certificate of Analysis) is a formal document that attests to Sodium Glycerophosphate's compliance with Sodium Glycerophosphate specifications and serves as a tool for batch-level quality control.
Sodium Glycerophosphate CoA mostly includes findings from lab analyses of a specific batch. For each Sodium Glycerophosphate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Sodium Glycerophosphate may be tested according to a variety of international standards, such as European Pharmacopoeia (Sodium Glycerophosphate EP), Sodium Glycerophosphate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Sodium Glycerophosphate USP).
LOOKING FOR A SUPPLIER?
Comment (7)
